«

»

ICARE Social Media Post June 2020

Advances in Treatment for BRCA-Mutated Triple Negative Breast Cancer

image_print

In a study of 914 women with different breast cancer subtypes, overall pathologic complete response rates were:

  • Higher in those with BRCA1/2 mutations (60.4% versus 46.7%)
  • No differences were seen in those with mutations in other inherited cancer genes
  • Among patients with triple-negative breast cancer, BRCA1/2 mutations had highest response rates to treatment in both study arms (Arm 1: 74.3%, Arm 2: 64.7%) compared to non-carriers (Arm 1: 47%; Arm 2: 45%)
  • Among those without triple negative disease, BRCA1/2 carriers had higher response rates compared to non-carriers (31.8% vs 11.9%)
  • Both platinum-based and non-platinum-based treatment may be of benefit to BRCA1/2 carriers with triple negative breast cancer in the neoadjuvant setting, but additional studies are needed to further evaluate these findings

Check out the original article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2762579

Permanent link to this article: https://inheritedcancer.net/post61920/